In a filing, Cyclacel Pharmaceuticals Inc revealed its Interim CEO Lazar David E. unloaded Company’s shares for reported $5.51 million on Feb 26 ’25. In the deal valued at $0.03 per share,194,628,820 shares were sold. As a result of this transaction, Lazar David E. now holds 0 shares worth roughly $0.0.
Ladenburg Thalmann began covering CYCC with “Buy” recommendation on September 07, 2018. H.C. Wainwright started covering the stock on October 16, 2015. It rated CYCC as “a Buy”.
Price Performance Review of CYCC
On Friday, Cyclacel Pharmaceuticals Inc [NASDAQ:CYCC] saw its stock fall -38.84% to $0.37. Over the last five days, the stock has lost -77.30%. Cyclacel Pharmaceuticals Inc shares have fallen nearly -93.85% since the year began. Nevertheless, the stocks have fallen -98.93% over the past one year. While a 52-week high of $39.84 was reached on 01/03/25, a 52-week low of $0.58 was recorded on 06/06/25. SMA at 50 days reached $3.1863, while 200 days put it at $7.8023.
Levels Of Support And Resistance For CYCC Stock
The 24-hour chart illustrates a support level at 0.2619, which if violated will result in even more drops to 0.1537. On the upside, there is a resistance level at 0.5691. A further resistance level may holdings at 0.7681. The Relative Strength Index (RSI) on the 14-day chart is 22.57, which indicates oversold technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.6606, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 99.04%. Stochastics %K at 3.70% indicates the stock is a buying.
The most recent change occurred on February 04, 2010 when Roth Capital began covering the stock and recommended ‘”a Buy”‘ rating along with a $7 price target.
